Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 9(10): e110054, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25333274

RESUMO

Homocysteinylation of lysine residues by homocysteine thiolactone (HCTL), a reactive homocysteine metabolite, results in protein aggregation and malfunction, and is a well-known risk factor for cardiovascular, autoimmune and neurological diseases. Human plasma paraoxonase-1 (PON1) and bleomycin hydrolase (Blmh) have been reported as the physiological HCTL detoxifying enzymes. However, the catalytic efficiency of HCTL hydrolysis by Blmh is low and not saturated at 20 mM HCTL. The catalytic efficiency of PON1 for HCTL hydrolysis is 100-fold lower than that of Blmh. A homocysteine thiolactonase (HCTLase) was purified from human liver and identified by mass spectrometry (MS) as the previously described human biphenyl hydrolase-like protein (BPHL). To further characterize this newly described HCTLase activity, BPHL was expressed in Escherichia coli and purified. The sequence of the recombinant BPHL (rBPHL) and hydrolytic products of the substrates HCTL and valacyclovir were verified by MS. We found that the catalytic efficiency (kcat/Km) of rBPHL for HCTL hydrolysis was 7.7 × 10(4) M(-1)s(-1), orders of magnitude higher than that of PON1 or Blmh, indicating a more significant physiological role for BPHL in detoxifying HCTL.


Assuntos
Arildialquilfosfatase/metabolismo , Hidrolases de Éster Carboxílico/metabolismo , Fígado/enzimologia , Arildialquilfosfatase/genética , Hidrolases de Éster Carboxílico/genética , Humanos
2.
J Lipid Res ; 55(6): 1173-8, 2014 06.
Artigo em Inglês | MEDLINE | ID: mdl-24711634

RESUMO

HDL-associated paraoxonase-1 (PON1) is an enzyme whose activity is associated with cerebrovascular disease. Common PON1 genetic variants have not been consistently associated with cerebrovascular disease. Rare coding variation that likely alters PON1 enzyme function may be more strongly associated with stroke. The National Heart, Lung, and Blood Institute Exome Sequencing Project sequenced the coding regions (exomes) of the genome for heart, lung, and blood-related phenotypes (including ischemic stroke). In this sample of 4,204 unrelated participants, 496 had verified, noncardioembolic ischemic stroke. After filtering, 28 nonsynonymous PON1 variants were identified. Analysis with the sequence kernel association test, adjusted for covariates, identified significant associations between PON1 variants and ischemic stroke (P = 3.01 × 10(-3)). Stratified analyses demonstrated a stronger association of PON1 variants with ischemic stroke in African ancestry (AA) participants (P = 5.03 × 10(-3)). Ethnic differences in the association between PON1 variants with stroke could be due to the effects of PON1Val109Ile (overall P = 7.88 × 10(-3); AA P = 6.52 × 10(-4)), found at higher frequency in AA participants (1.16% vs. 0.02%) and whose protein is less stable than the common allele. In summary, rare genetic variation in PON1 was associated with ischemic stroke, with stronger associations identified in those of AA. Increased focus on PON1 enzyme function and its role in cerebrovascular disease is warranted.


Assuntos
Arildialquilfosfatase/genética , Isquemia Encefálica/genética , Exoma , Variação Genética , Acidente Vascular Cerebral/genética , Arildialquilfosfatase/metabolismo , População Negra/genética , Isquemia Encefálica/enzimologia , Feminino , Humanos , Masculino , Acidente Vascular Cerebral/enzimologia
3.
Chem Biol Interact ; 203(1): 257-64, 2013 Mar 25.
Artigo em Inglês | MEDLINE | ID: mdl-23085349

RESUMO

Individuals aboard jet aircraft may be exposed to potentially toxic triaryl organophosphate anti-wear lubricant additives (TAPs) that are converted by cytochromes P450 into toxic metabolites. Consequences of exposure could be reduced by using less toxic TAPs. Our goal was to determine whether an in vitro assay for inhibition of butyrylcholinesterase (BChE) by bioactivated TAPs would be predictive of inhibition of serine active-site enzymes in vivo. The in vitro assay involved TAP bioactivation with liver microsomes and NADPH, followed by incubation with human BChE and measurement of BChE activity. Of 19 TAPs tested, tert-butylated isomers produced the least BChE inhibition. To determine the relevance of these results in vivo, mice were exposed to Durad 125 (D125; a commercial mixture of TAP esters) or to TAPs demonstrating low or no BChE inhibition when assayed in vitro. Inhibition of BChE by bioactivated TAPs in vitro correlated well with inhibition of other serine active-site enzymes in vivo, with the exception of brain acetylcholinesterase and neuropathy target esterase (NTE), which were not inhibited by any TAP tested following single exposures. A recombinant catalytic domain of NTE (rNEST) exhibited classical kinetic properties of NTE. The metabolite of tri-(o-cresyl) phosphate (ToCP), 2-(o-cresyl)-4H-1,3,2-benzodioxaphosphoran-2-one (CBDP), inhibited rNEST in vitro, but with an IC(50) value almost 6-times higher than for inhibition of BChE. Physiologically-relevant concentrations of the flavonoid naringenin dramatically reduced D125 bioconversion in vitro. The in vitro assay should provide a valuable tool for prescreening candidate TAP anti-wear additives, identifying safer additives and reducing the number of animals required for in vivo toxicity testing.


Assuntos
Lubrificantes/toxicidade , Compostos Organofosforados/toxicidade , Aeronaves , Animais , Biotransformação , Butirilcolinesterase/metabolismo , Hidrolases de Éster Carboxílico/antagonistas & inibidores , Inibidores da Colinesterase/química , Inibidores da Colinesterase/metabolismo , Inibidores da Colinesterase/toxicidade , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Humanos , Lubrificantes/química , Lubrificantes/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Microssomos Hepáticos/metabolismo , Compostos Organofosforados/química , Compostos Organofosforados/metabolismo , Proteínas Recombinantes/antagonistas & inibidores
4.
Neurotoxicology ; 32(5): 656-60, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21767566

RESUMO

There are ongoing events where aircraft engine lubricant containing tricresyl phosphates (TCPs) contaminates aircraft cabins. Some individuals have experienced tremors or other neurological symptoms that may last for many months following exposures. Mass spectrometric (MS) protocols are being developed to determine the percentage of "biomarker proteins" that are modified by such exposures, specifically on active site serines. Both plasma butyrylcholinesterase (BChE) and red cell acylpeptide hydrolase (APH) are readily inhibited by 2-(ortho-cresyl)-4H-1,3,2-benzodioxaphosphoran-2-one (CBDP) or phenyl saligenin cyclic phosphate (PSP) and have the potential to provide information about the level of exposure of an individual. We have developed immunomagnetic bead-based single-step purification protocols for both BChE and APH and have characterized the active site serine adducts of BChE by MS.


Assuntos
Exposição Ambiental/efeitos adversos , Compostos Organofosforados/sangue , Biomarcadores/sangue , Butirilcolinesterase/sangue , Eletroforese em Gel de Poliacrilamida/métodos , Humanos , Espectrometria de Massas/métodos , Peptídeo Hidrolases/sangue
5.
Adv Exp Med Biol ; 660: 37-45, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20221869

RESUMO

Expression and purification of recombinant human paraoxonase-1 (rHuPON1) from bacterial systems have proven elusive. Most systems for successful production of recombinant PON1 have relied on either eukaryotic expression in baculovirus or prokaryotic expression of synthetic, gene-shuffled rabbit-mouse-human PON1 hybrid molecules. We review here methods and protocols for the production of pure, native rHuPON1 using an E. coli expression system followed by conventional column chromatographic purification. The resulting rHuPON1 is stable, active, and capable of protecting PON1 knockout mice (PON1(-/-)) from exposure to high levels of the organophosphorus (OP) compound diazoxon. Bacterially-derived rHuPON1 can be produced in large quantities and lacks the glycosylation of eukaryotic systems that produces immunogenic complications when used as a therapeutic. The rHuPON1 should be useful for treating insecticide OP exposures and reducing risks of other diseases resulting from low PON1 status. The ease of mutagenesis in bacterial systems will also allow for the generation and screening of rHuPON1 variants with enhanced catalytic efficiencies against nerve agents and other OP compounds.


Assuntos
Arildialquilfosfatase/metabolismo , Escherichia coli/metabolismo , Engenharia Genética/métodos , Animais , Arildialquilfosfatase/genética , Catálise , Glicosilação , Humanos , Inseticidas/farmacologia , Cinética , Camundongos , Camundongos Knockout , Compostos Organofosforados/farmacologia , Proteínas Recombinantes/química
6.
Adv Exp Med Biol ; 660: 61-71, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20221871

RESUMO

Over 1 billion pounds of organophosphorus (OP) chemicals are manufactured worldwide each year, including 70 million pounds of pesticides sprayed in the US. Current methods to monitor environmental and occupational exposures to OPs such as chlorpyrifos (CPS) have limitations, including low specificity and sensitivity, and short time windows for detection. Biomarkers for the OP tricresyl phosphate (TCP), which can contaminate bleed air from jet engines and cause an occupational exposure of commercial airline pilots, crewmembers and passengers, have not been identified. The aim of our work has been to identify, purify, and characterize new biomarkers of OP exposure. Butyrylcholinesterase (BChE) inhibition has been a standard for monitoring OP exposure. By identifying and characterizing molecular biomarkers with longer half-lives, we should be able to clinically detect TCP and OP insecticide exposure after longer durations of time than are currently possible. Acylpeptide hydrolase (APH) is a red blood cell (RBC) cytosolic serine proteinase that removes N-acetylated amino acids from peptides and cleaves oxidized proteins. Due to its properties, it is an excellent candidate for a biomarker of exposure. We have been able to purify APH and detect inhibition by both CPS and metabolites of TCP. The 120-day lifetime of the RBC offers a much longer window for detecting exposure. The OP-modified serine conjugate in the active site tryptic peptide has been characterized by mass spectrometry. This research uses functional proteomics and enzyme activities to identify and characterize useful biomarkers of neurotoxic environmental and occupational OP exposures.


Assuntos
Biomarcadores/metabolismo , Compostos Organofosforados/toxicidade , Praguicidas/toxicidade , Sequência de Aminoácidos , Animais , Butirilcolinesterase/metabolismo , Inibidores da Colinesterase/farmacologia , Eritrócitos/metabolismo , Humanos , Espectrometria de Massas/métodos , Dados de Sequência Molecular , Peptídeo Hidrolases/análise , Peptídeo Hidrolases/metabolismo , Proteômica/métodos , Tritolil Fosfatos/química
7.
Am J Trop Med Hyg ; 81(2): 348-55, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19635897

RESUMO

Infection with Plasmodium vivax is usually treated with chloroquine, but parasites are often exposed inadvertently to sulfadoxine-pyrimethamine. To infer patterns of selection and spread of resistant parasites in natural populations, we determined haplotypes of P. vivax dihydropteroate synthase ( dhps ) alleles that could confer resistance to sulfadoxine. We amplified the P. vivax pyrophosphokinase ( pppk )- dhps region and its flanking intergenic regions from 92 contemporary global isolates. Introns and exons of pppk-dhps were highly polymorphic, as were the flanking intergenic regions. Eighteen haplotypes were associated with wild-type alleles, but several different putatively sulfadoxine-resistant alleles have arisen in areas of intensive sulfadoxine-pyrimethamine use. Even when they encoded changes to the same amino acid, these mutant alleles were associated with multiple different haplotypes. Two main conclusions can be drawn from these data. First, dhps alleles resistant to sulfadoxine have arisen multiple times under drug pressure. Second, there has been convergent evolution of a variety of alleles that could confer resistance to sulfa drugs.


Assuntos
Antimaláricos/farmacologia , Di-Hidropteroato Sintase/genética , Di-Hidropteroato Sintase/metabolismo , Resistência a Medicamentos/genética , Plasmodium vivax/enzimologia , Plasmodium vivax/genética , Animais , DNA de Protozoário/genética , Regulação Enzimológica da Expressão Gênica , Genoma de Protozoário , Haplótipos , Indonésia , Mutação , Tailândia
8.
Proc Natl Acad Sci U S A ; 105(35): 12780-4, 2008 Sep 02.
Artigo em Inglês | MEDLINE | ID: mdl-18711144

RESUMO

The high-density lipoprotein-associated enzyme paraoxonase 1 (PON1) hydrolyzes lactones, aromatic esters, and neurotoxic organophosphorus (OP) compounds, including insecticide metabolites and nerve agents. Experiments with mice lacking PON1 (PON1(-/-) mice) have established that plasma PON1 protects against chlorpyrifos/chlorpyrifos-oxon and diazinon/diazoxon (DZO) exposure but does not protect against parathion/paraoxon or nerve agents. The catalytic efficiency of PON1 determines whether or not it will protect against a given OP exposure. Expression of active recombinant human PON1 (rHuPON1) in Escherichia coli provides a system in which PON1 can be engineered to achieve a catalytic efficiency sufficient to protect against or treat specific OP exposures. Here, we describe the generation of highly purified engineered rHuPON1(K192) that protects against DZO exposure when injected into PON1(-/-) mice. The injected rHuPON1 is nontoxic, persists in serum for at least 2 days after injection, and provides protection against DZO exposures of at least three times the median lethal dose value.


Assuntos
Arildialquilfosfatase/isolamento & purificação , Arildialquilfosfatase/farmacologia , Escherichia coli/metabolismo , Intoxicação por Organofosfatos , Engenharia de Proteínas , Proteínas Recombinantes/isolamento & purificação , Proteínas Recombinantes/farmacologia , Animais , Arildialquilfosfatase/sangue , Arildialquilfosfatase/metabolismo , Eletroforese em Gel de Poliacrilamida , Humanos , Hidrólise , Injeções Intraperitoneais , Cinética , Camundongos , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/metabolismo , Proteína Estafilocócica A/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...